...
首页> 外文期刊>Vaccine >The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine
【24h】

The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine

机译:新世界灵长类动物Aotus nancymae,作为检查原型产肠毒素大肠杆菌亚单位疫苗免疫原性的模型

获取原文
获取原文并翻译 | 示例

摘要

The colonization factors (CF) of enterotoxigenic Escherichia coli (ETEC) are being targeted for inclusion in a multi-subunit ETEC vaccine. This study was designed to examine the preclinical safety and immunogenicity of CF CS6, encapsulated in a biodegradable poly(dl-lactide-co-glycolide) (meCS6), and administered in the presence or absence of a mutated heat-labile enterotoxin, LT(R192G), in the non-human primate, Aotus nancymae. A. nancymae were inoculated intranasally (IN) with meCS6 (200mug; positive control), or intragastrically (IG) with meCS6 (200 or 1000mug) with or without 2mug LT(R192G) in three doses given at 2-week intervals. In a second experiment, A. nancymae were inoculated IG with 950mug of meCS6 with or without 2mug LT(R192G) in four doses given every 48h. Blood was collected to assess anti-CS6 and -LT serum immunoglobulin G (IgG) and IgA responses and safety variables (complete blood count and chemistry). Safety parameters were unchanged from baseline following all vaccinations. In Experiment 1, a dose-related serologic response to CS6 was observed; 78.6 and 57.1% of monkeys given 1000mug meCS6 (n=14) had a serum IgG and IgA response, respectively, compared to only 28.6% of monkeys given 200mug meCS6 (n=14) with a serum IgG and IgA response. No significant effect on the number of responders or the magnitude of responses was observed with the addition of LT(R192G). The three-dose, 2-week regimen with 1000mug meCS6 was more effective at eliciting an immune response than the four-dose, 48-h regimen with 950mug meCS6. Results from this study indicate that A. nancymae provide a useful ETEC preclinical safety and immunogenicity model.
机译:产肠毒素大肠杆菌(ETEC)的定居因子(CF)的目标是包含在多亚基ETEC疫苗中。这项研究旨在检查CF CS6的临床前安全性和免疫原性,将其封装在可生物降解的聚(dl-丙交酯-共-乙交酯)(meCS6)中,并在存在或不存在热不稳定突变型肠毒素LT( R192G),在非人类灵长类动物Aotus nancymae中。鼻内曲霉(A)用meCS6(200mug;阳性对照)鼻内(IN)接种,或胃内(me)含或不含2mug LT(R192G)的meCS6(200或1000mug)接种,每两周间隔3剂。在第二个实验中,每48h给予四次剂量的950 ug meCS6含或不含2mug LT(R192G)的IG疫苗接种。收集血液以评估抗CS6和-LT血清免疫球蛋白G(IgG)和IgA反应以及安全性变量(全血细胞计数和化学性质)。接种所有疫苗后,安全参数与基线相比没有变化。在实验1中,观察到了对CS6剂量相关的血清学反应。分别接受1000mug meCS6(n = 14)的猴子中有78.6%和57.1%的猴子分别具有血清IgG和IgA反应,相比之下,接受200mug meCS6(n = 14)的猴子仅28.6%具有血清IgG和IgA反应。添加LT(R192G)不会对应答者的数量或应答的大小产生显着影响。含1000mug meCS6的三剂量,两周方案比含950mug meCS6的四剂量,48小时方案更能引起免疫反应。这项研究的结果表明,南极芽胞杆菌提供了有用的ETEC临床前安全性和免疫原性模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号